Two recent reviews reveal the potential use of ceragenins or cationic selective antimicrobials to treat cystic fibrosis patients.
N8 says one of the lead ceragenin compounds, CSA-13, has exhibited particularly potent antimicrobial properties and is rapidly bactericidal, fungicidal and virucidal against a wide array of pathogens, including multidrug resistant strains of Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa). CSA-13 has also demonstrated capacity to both prevent and remove bacterial and fungal biofilms, which are nearly impossible to eradicate utilizing conventional antibiotics. They note that preclinical testing has displayed CSA-13?s high potency at low doses, and absence of toxic response at doses much higher than are expected to be clinically necessary.
